Abbott

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Abbott 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. 

CEO
Robert B. Ford
CEORobert B. Ford
Employees
115,000
Employees115,000
Headquarters
Abbott Park, Illinois
HeadquartersAbbott Park, Illinois
Founded
1888
Founded1888
Employees
115,000
Employees115,000

ABT Key Statistics

Market cap
176.80B
Market cap176.80B
Price-Earnings ratio
27.17
Price-Earnings ratio27.17
Dividend yield
2.38%
Dividend yield2.38%
Average volume
9.64M
Average volume9.64M
High today
$102.35
High today$102.35
Low today
$96.79
Low today$96.79
Open price
$101.18
Open price$101.18
Volume
359.94K
Volume359.94K
52 Week high
$139.06
52 Week high$139.06
52 Week low
$96.79
52 Week low$96.79

Stock Snapshot

As of today, Abbott(ABT) shares are valued at $96.85. The company's market cap stands at 176.8B, with a P/E ratio of 27.17 and a dividend yield of 2.4%.

On 2026-04-16, Abbott(ABT) stock moved within a range of $96.79 to $102.35. With shares now at $96.85, the stock is trading +0.1% above its intraday low and -5.4% below the session's peak.

Trading volume for Abbott(ABT) stock has reached 359.94K, versus its average volume of 9.64M.

The stock's 52-week range extends from a low of $96.79 to a high of $139.06.

The stock's 52-week range extends from a low of $96.79 to a high of $139.06.

ABT News

Seeking Alpha 42m
Abbott cuts earnings outlook to reflect Exact Sciences buyout

Shares of Abbott Laboratories (ABT) dipped in the premarket on Thursday after the MedTech giant lowered its full-year earnings outlook to reflect its recent acq...

Abbott cuts earnings outlook to reflect Exact Sciences buyout
Nasdaq 49m
Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences

(RTTNews) - Abbott (ABT) said it now projects full-year 2026 adjusted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exac...

Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences
Nasdaq 1h
Abbott Laboratories Reports Retreat In Q1 Profit

(RTTNews) - Abbott Laboratories (ABT) reported earnings for first quarter that Drops, from the same period last year The company's earnings totaled $1.07 billi...

Abbott Laboratories Reports Retreat In Q1 Profit

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
25%
Sell
0%

More ABT News

Nasdaq 3h
Abbott Laboratories Q1 26 Earnings Conference Call At 9:00 AM ET

(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2026, to discuss Q1 26 earnings results. To access the live webcas...

Abbott Laboratories Q1 26 Earnings Conference Call At 9:00 AM ET
Simply Wall St 2d
Abbott’s Exact Sciences Deal Reshapes Diagnostics Value Story For Investors

Abbott Laboratories agreed to acquire Exact Sciences for $21b, marking the largest healthcare and diagnostic deal in two years. The transaction expands Abbott’...

Abbott’s Exact Sciences Deal Reshapes Diagnostics Value Story For Investors
Benzinga 2d
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings

Abbott Laboratories (NYSE:ABT) will release earnings for its first quarter before the opening bell on Thursday, April 16. Analysts expect the Abbott Park, Illi...

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings
TipRanks 6d
Abbott Laboratories: Solid Q1 Setup and Resilient MedTech/Diagnostics Support Path to 2026 Targets Amid Manageable Geopolitical Headwinds

Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories and keeping the price target at $137.00. Easter Sale - 70% Off TipRanks Unloc...

Simply Wall St 6d
How Abbott Baby Formula Verdict and Rising Litigation Risk May Reshape Abbott Laboratories' Investment Profile

In late March 2026, a Chicago jury ordered Abbott Laboratories to pay US$53 million in compensatory damages to families alleging the company failed to adequatel...

How Abbott Baby Formula Verdict and Rising Litigation Risk May Reshape Abbott Laboratories' Investment Profile

People also own

Based on the portfolios of people who own ABT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.